Quick Answer
Polaryx Therapeutics, Inc. reported R&D Expense of $6.27 million for fiscal year 2025.
Polaryx Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $6.27M | +122.9% |
| 2024 | $2.81M | — |
- Polaryx Therapeutics, Inc. showed an increase of +122.9% in R&D Expense compared to the prior fiscal year.
- Over the 2024–2025 period, Polaryx Therapeutics, Inc.’s r&d expense has grown by 122.9% (from $2.81 million to $6.27 million).
- The most recent figure is from Polaryx Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: